NCT06970132View on ClinicalTrials.gov

Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Advanced Solid Tumor
Interventions
DRUG

SY-5933

KRAS p.G12C inhibitor

DRUG

CT-707

Focal Adhesion Kinase (FAK) inhibitor

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Shouyao Holdings (Beijing) Co. LTD

OTHER

NCT06970132 - Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation | Biotech Hunter | Biotech Hunter